Lamosyn 25 Tablet

Lamosyn 25 is commonly prescribed as adjunctive therapy for partial seizures, generalized seizures including tonic-clonic and absence seizures, as well as for the maintenance treatment of bipolar disorder to delay the occurrence of mood episodes. The tablet should be administered orally, with dosing individualized based on clinical response and tolerability. Initiation and dose escalation must be gradual to minimize the risk of serious skin reactions, including Stevens-Johnson syndrome.

Common adverse effects include dizziness, headache, blurred vision, nausea, and rash. Patients should be advised to report any signs of hypersensitivity or severe rash immediately. Caution is warranted in patients with hepatic or renal impairment, and potential drug interactions should be assessed prior to initiation. Lamosyn 25 should be used under strict medical supervision with regular monitoring to ensure safety and efficacy.